Comparative Proteomic Profiling Using Two-Dimensional Gel Electrophoresis and Identification via LC-MS/MS Reveals Novel Protein Biomarkers to Identify Aggressive Subtypes of WHO Grade I Meningioma

Abstract

Background Meningomas represent the most common primary intracranial tumor. The majority are benign World Health Organization (WHO) Grade I lesions, but a subset of these behave in an aggressive manner. Protein biomarkers are needed to distinguish aggressive from benign Grade I lesions.

Materials and Methods Pooled protein lysates were derived from five clinically aggressive Grade I and five typically benign WHO Grade I tumors snap frozen at the time of surgery. Proteins were separated in each group using two-dimensional gel electrophoresis (2DGE) and protein spots of interest were identified using liquid chromatography–mass spectrometry (LC-MS). Potential biomarker candidates were validated using western blot assays in individual tumor samples and by tissue microarray (TMA).

Results Seven candidate biomarkers were obtained from the 2DGE and validated via western blot and TMA. Biomarker validation data allowed for the creation of predictive models using binary logistical regression that correctly identified 85.9% of aggressive tumors within the larger cohort of Grade I meningioma.

Conclusion Simple protein separation by 2DGE and identification of candidate biomarkers by LC-MS allowed for the identification of seven candidate biomarkers that when used in predictive models accurately distinguish aggressive from benign behavior in WHO Grade I meningioma.

Keywords

meningioma - proteomic - two-dimensional gel electrophoresis - mass spectrometry - biomarker discovery

• References

• 1 Cahill KS, Claus EB. Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Clinical article. J Neurosurg 2011; 115 (02) 259-267
• 2 Vernooij MW, Ikram MA, Tanghe HL. , et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007; 357 (18) 1821-1828
• 3 Nakasu S, Hirano A, Shimura T, Llena JF. Incidental meningiomas in autopsy study. Surg Neurol 1987; 27 (04) 319-322
• 4 Louis DN, Ohgaki H, Wiestler OD. , et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (02) 97-109
• 5 Backer-Grøndahl T, Moen BH, Torp SH. The histopathological spectrum of human meningiomas. Int J Clin Exp Pathol 2012; 5 (03) 231-242
• 6 Gay E, Lages E, Ramus C. , et al. The heterogeneity of meningioma revealed by multiparameter analysis: infiltrative and non-infiltrative clinical phenotypes. Int J Oncol 2011; 38 (05) 1287-1297
• 7 McCarthy BJ, Davis FG, Freels S. , et al. Factors associated with survival in patients with meningioma. J Neurosurg 1998; 88 (05) 831-839
• 8 McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg 2010; 112 (05) 925-933
• 9 Nakasu S, Fukami T, Jito J, Nozaki K. Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol 2009; 26 (02) 69-72
• 10 Pérez-Magán E, Campos-Martín Y, Mur P. , et al. Genetic alterations associated with progression and recurrence in meningiomas. J Neuropathol Exp Neurol 2012; 71 (10) 882-893
• 11 Serna E, Morales JM, Mata M. , et al. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma. PLoS One 2013; 8 (06) e67291
• 12 Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957; 20 (01) 22-39
• 13 Cerdá-Nicolás M, López-Gineś C, Pérez-Bacete M, Barcia-Salorio JL, Llombart-Bosch A. Histopathological and cytogenetic findings in benign, atypical and anaplastic human meningiomas: a study of 60 tumors. J Neurooncol 2000; 47 (02) 99-108
• 14 Bouamrani A, Ramus C, Gay E. , et al. Increased phosphorylation of vimentin in noninfiltrative meningiomas. PLoS One 2010; 5 (02) e9238
• 15 Stuart JE, Lusis EA, Scheck AC. , et al. Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays. J Neuropathol Exp Neurol 2011; 70 (01) 1-12
• 16 Wibom C, Mörén L, Aarhus M. , et al. Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol 2009; 94 (03) 321-331
• 17 Tang F, Li W, Chen Y, Wang D, Han J, Liu D. Downregulation of hnRNP K by RNAi inhibits growth of human lung carcinoma cells. Oncol Lett 2014; 7 (04) 1073-1077
• 18 Bomsztyk K, Denisenko O, Ostrowski J. hnRNP K: one protein multiple processes. BioEssays 2004; 26 (06) 629-638
• 19 Ostrowski J, Bomsztyk K. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br J Cancer 2003; 89 (08) 1493-1501
• 20 Cunningham CC, Stossel TP, Kwiatkowski DJ. Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science 1991; 251 (4998): 1233-1236
• 21 Thompson CC, Ashcroft FJ, Patel S. , et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007; 56 (01) 95-106
• 22 Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 2004; 61 (19-20): 2614-2623
• 23 Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006; 16 (11) 137R-157R
• 24 Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001; 20 (51) 7486-7493
• 25 Garín MI, Chu CC, Golshayan D, Cernuda-Morollón E, Wait R, Lechler RI. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109 (05) 2058-2065
• 26 Yang J, Ramnath N, Moysich KB. , et al. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer 2006; 6: 203
• 27 Rubinstein N, Alvarez M, Zwirner NW. , et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004; 5 (03) 241-251
• 28 Okamoto H, Li J, Vortmeyer AO. , et al. Comparative proteomic profiles of meningioma subtypes. Cancer Res 2006; 66 (20) 10199-10204
• 29 Gao R, Yu Y, Inoue A, Widodo N, Kaul SC, Wadhwa R. Heterogeneous nuclear ribonucleoprotein K (hnRNP-K) promotes tumor metastasis by induction of genes involved in extracellular matrix, cell movement, and angiogenesis. J Biol Chem 2013; 288 (21) 15046-15056
• 30 Azuma T, Koths K, Flanagan L, Kwiatkowski D. Gelsolin in complex with phosphatidylinositol 4,5-bisphosphate inhibits caspase-3 and -9 to retard apoptotic progression. J Biol Chem 2000; 275 (06) 3761-3766
• 31 Kothakota S, Azuma T, Reinhard C. , et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997; 278 (5336): 294-298
• 32 Clark VE, Erson-Omay EZ, Serin A. , et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013; 339 (6123): 1077-1080
• 33 Riobó N, Lu K, Ai X, Haines G, Emerson CP. Phosphoinositide 3-kinase and Akt are essential for sonic hedgehog signaling. Proc Natl Acad Sci U S A 2006; 103 (12) 4505-4510
• 34 Ciarlo M, Benelli R, Barbieri O. , et al. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells. Int J Cancer 2012; 131 (03) 582-590
• 35 Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 2010; 11 (05) 353-365